Home > Insider Trading > Filing (0001209191-19-003997)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1370053	Anaptysbio Inc	ANAB	Pharmaceutical Preparations (2834)	203828755

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1654495	Hamza Suria	C/O Anaptysbio, Inc. 10421 Pacific Center Court, Suite 200 San Diego CA 92121	President, Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2019-01-14	40,000	$1.12	70,064	No	4	M	Direct
Common Stock	Disposition	2019-01-14	27,760	$70.65	42,304	No	4	S	Direct
Common Stock	Disposition	2019-01-14	12,240	$71.10	30,064	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2019-01-14	40,000	$0.00	40,000	$1.12

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
89,284		2022-01-31	No	4	M	Direct

Footnotes

The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.99 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.00 to $71.60 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The stock option is fully vested and immediately exercisable.
In addition to the remaining options to purchase 89,284 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 705,554 shares of common stock, which options vest according to their terms, and (ii) 30,064 shares of common stock held directly.